Skip to main content

Pulmonary fibrosis: new insights

Edited by:

Paolo Spagnolo: University of Padua, Italy 
Argyrios Tzouvelekis: University of Patras, Greece

Submission Status: Open   |   Submission Deadline: 30 June 2024


Respiratory Research is calling for submissions to our collection on Pulmonary fibrosis: new insights. 
 

This Collection supports and amplifies research related to SDG 3.

Image credit: Paolo Spagnolo

About the collection

Respiratory Research is calling for submissions to our collection on Pulmonary fibrosis: new insights. The field of pulmonary fibrosis has gone through substantial changes in recent years, with several traditional views on disease pathogenesis and treatment being challenged and replaced by more convincing concepts. The collection seeks manuscripts that address the diagnosis, characterization and management of pulmonary fibrosis, with emphasis on novel concepts of disease pathogenesis, predictors of disease behavior and response to treatment and developmental drugs.

  1. Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. ...

    Authors: Jaume Bordas-Martinez, Neus Salord, Vanesa Vicens-Zygmunt, João Carmezim, Sandra Pérez, Eliseo Prado, María Calvo, Rosana Blavia, Guadalupe Bermudo, Salud Santos, Carmen Monasterio and María Molina-Molina
    Citation: Respiratory Research 2024 25:247
  2. In familial pulmonary fibrosis (FPF) at least two biological relatives are affected. Patients with FPF have diverse clinical features.

    Authors: Hanna Jaula, Lauri Mattila, Elisa Lappi-Blanco, Johanna Salonen, Hannu Vähänikkilä, Lauri Ahvenjärvi, Jukka S. Moilanen, Outi Kuismin, Terttu Harju and Riitta Kaarteenaho
    Citation: Respiratory Research 2024 25:239
  3. Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with ...

    Authors: Katharina Buschulte, Hans-Joachim Kabitz, Lars Hagmeyer, Peter Hammerl, Albert Esselmann, Conrad Wiederhold, Dirk Skowasch, Christoph Stolpe, Marcus Joest, Stefan Veitshans, Marc Höffgen, Phillen Maqhuzu, Larissa Schwarzkopf, Andreas Hellmann, Michael Pfeifer, Jürgen Behr…
    Citation: Respiratory Research 2024 25:113
  4. Although some studies have indicated that Psoriasis could contribute to the risk of idiopathic pulmonary fibrosis (IPF), no study has reported a clear causal association between them. Our aim was to explore th...

    Authors: Lingli Chen, Yujie Wei, Mengjin Hu, Yile Liu and Xiangrong Zheng
    Citation: Respiratory Research 2024 25:101
  5. Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with high mortality. Low muscle mass, frailty and sarcopenia lead to functional impairment that negatively impact quality of life and sur...

    Authors: Meenakshi Sridhar, Sandeep Bodduluri, Lanier O’Hare, Scott Blumhoff, Maria del Pilar Acosta Lara, Joao A. de Andrade, Young-Il Kim, Tracy Luckhardt, MerryLynn McDonald and Tejaswini Kulkarni
    Citation: Respiratory Research 2024 25:81
  6. Breath testing using an electronic nose has been recognized as a promising new technique for the early detection of lung cancer. Imbalanced data are commonly observed in electronic nose studies, but methods to...

    Authors: Ke-Cheng Chen, Shuenn-Wen Kuo, Ruei-Hao Shie and Hsiao-Yu Yang
    Citation: Respiratory Research 2024 25:32
  7. Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on...

    Authors: Katharina Buschulte, Hans-Joachim Kabitz, Lars Hagmeyer, Peter Hammerl, Albert Esselmann, Conrad Wiederhold, Dirk Skowasch, Christoph Stolpe, Marcus Joest, Stefan Veitshans, Marc Höffgen, Phillen Maqhuzu, Larissa Schwarzkopf, Andreas Hellmann, Michael Pfeifer, Jürgen Behr…
    Citation: Respiratory Research 2024 25:5
  8. Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) with unknown etiology, characterized by sustained damage repair of epithelial cells and abnormal activation of fibroblasts, ...

    Authors: Caoyuan Niu, Kai Xu, Yanan Hu, Yanling Jia, Yuexia Yang, Xiaoyue Pan, Ruyan Wan, Hui Lian, Qiwen Wang, Juntang Yang, Yajun Li, Ivan Rosas, Lan Wang and Guoying Yu
    Citation: Respiratory Research 2023 24:318
  9. Several observational studies have found that physical inactivity and sedentary time are associated with idiopathic pulmonary fibrosis (IPF) risk. However, the causality between them still requires further inv...

    Authors: Wanyang Lei, Mei Yang, Ziyu Yuan, Runlin Feng, Xiao Kuang, Zhiqiang Liu, Zongqi Deng, Xianglin Hu and Wenlin Tai
    Citation: Respiratory Research 2023 24:291
  10. Mediastinal lymph node enlargement is prevalent in patients with idiopathic pulmonary fibrosis (IPF). Studies investigating whether this phenomenon reflects specific immunologic activation are lacking.

    Authors: Theodoros Karampitsakos, Apostolos Galaris, Serafeim Chrysikos, Ourania Papaioannou, Ioannis Vamvakaris, Ilianna Barbayianni, Paraskevi Kanellopoulou, Sofia Grammenoudi, Nektarios Anagnostopoulos, Grigoris Stratakos, Matthaios Katsaras, Fotios Sampsonas, Katerina Dimakou, Effrosyni D. Manali, Spyridon Papiris, Bochra Tourki…
    Citation: Respiratory Research 2023 24:279
  11. Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associat...

    Authors: Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In ‘t Veen and Catharina C. Moor
    Citation: Respiratory Research 2023 24:271
  12. The role of the immune system in the pathobiology of Idiopathic Pulmonary Fibrosis (IPF) is controversial.

    Authors: Tamara Cruz, Núria Mendoza, Sandra Casas-Recasens, Guillaume Noell, Fernanda Hernandez-Gonzalez, Alejandro Frino-Garcia, Xavi Alsina-Restoy, María Molina, Mauricio Rojas, Alvar Agustí, Jacobo Sellares and Rosa Faner
    Citation: Respiratory Research 2023 24:236

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles, Data Notes, Case Reports, Study Protocols, and Database Articles.

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Pulmonary fibrosis: new insights" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they will handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.